GlobeNewsWire
28 Sept 2025, 04:20 UTC · 51w ago
Verdict
Headline takes no side. We score 867.HK +0.90 across three claims — strongly bullish.
+0.90strongly bullish
More positive than 94% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
China Medical System's ruxolitinib cream met its primary and key secondary endpoints in a Phase 3 clinical trial for mild to moderate atopic dermatitis (AD) in China.
More positive than 96% of claims this week
CMS is actively proceeding with the New Drug Application (NDA) for ruxolitinib cream in China following the trial results.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 76% of claims this week
Dermavon, a CMS subsidiary specializing in skin health, is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited.
More positive than 63% of claims this week
Which stocks this story touches
More positive than 94% of ticker scores this week
The company reported positive phase 3 clinical trial results for ruxolitinib cream in China.
More positive than 62% of ticker scores this week
The company's developed drug showed positive clinical results through a partner and maintains a strong regulatory footprint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
2d ago
—
No price for 867.HK right now — the quote feed didn't answer.
867.HK chart →
